-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: The main advantages of in vitro cell-killing experimental platforms
Author:
InnoModels
Release time:
2024-04-08
In the vast ocean of biomedical research, cell killing experimental platform occupies an important position. As an advanced experimental tool, as well as its unique technical features and significant advantages, the in vitro cell-killing experimental platform of InnoModels Biotechnology provides researchers with a more accurate and efficient means of research. In this paper, we will introduce the main advantages of InnoModels Biotechnology biocidal experimental platform and discuss its application prospects in biomedical research.
1、Highly simulate the in vivo environment
By simulating the physiological and pathological environments in the body, InnoModels' in vitro killing experiment platform makes the results of in vitro experiments closer to the real situation. This includes the simulation of the tumor microenvironment, the interaction between immune cells, and the metabolic process of drugs in the body. By highly simulating the in vivo environment, the platform is able to more accurately assess the cell killing effect and drug action mechanism.
2. Flexible and adjustable experimental conditions
Compared with the traditional experimental platforms, the InnoModels Biotechnology In Vitro Killing Experimental Platform has a higher degree of flexibility and adjustability. Researchers can freely adjust the experimental conditions according to their research needs, such as cell type, drug concentration, incubation time and so on. Such flexible experimental conditions enable researchers to comprehensively and systematically study the cell killing process and drug action mechanism.

3、Efficient experimental operation
InnoModels' in vitro cell-killing experimental platform adopts automated, high-throughput experimental operation, which greatly improves the experimental efficiency. With the automated liquid handling system, cell culture equipment and testing instruments, the platform is able to complete a large number of experiments in a short period of time, thus accelerating the research process.
4. Accurate experimental results
By introducing advanced imaging technology and data analysis methods, the platform makes the experimental results more accurate and reliable. Researchers can observe the cell killing process through a high-resolution microscope and use data analysis software to quantitatively analyze and interpret the experimental results. Such precise experimental results help researchers to better understand the cell killing mechanism and drug action mechanism.
5、Wide range of applications
InnoModels' in vitro cell-killing experimental platform has a wide range of applications in the field of biomedical research. The platform can be used to study tumor immunotherapy, antiviral drug screening, and autoimmune diseases. Through this platform, researchers can evaluate the cell killing effect of different therapeutic methods and screen potential drug candidates to provide strong support for clinical treatment.
In conclusion, with its advantages of highly simulated in vivo environment, flexible and adjustable experimental conditions, efficient experimental operation, accurate experimental results and wide range of applications, the InnoModels Biotechnology in vitro cell-killing experimental platform opens up new horizons for biomedical research. With the continuous development and improvement of the technology, it is believed that the platform will bring broader application prospects for cell therapy and drug screening.
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd